Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ$1.45-0.09 (-5.84%)
Market Cap
$246.44M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
655 of 924
Rank in Industry
40 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
IRWD Insider Trading Activity
IRWD Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $2,010,554 | 16 | 100 |
Related Transactions
| Martini Gregory S. | Chief Financial Officer | 0 | $0 | 1 | $21,212 | $-21,212 |
| Silver Ronald | Principal Accounting Officer | 0 | $0 | 2 | $34,471 | $-34,471 |
| Emany Sravan Kumar | SVP, COO and CFO | 0 | $0 | 1 | $44,884 | $-44,884 |
| McHugh Julie | director | 0 | $0 | 1 | $143,198 | $-143,198 |
| Davis Andrew | SVP, Chief Business Officer | 0 | $0 | 2 | $168,445 | $-168,445 |
| Shetzline Michael | CMO,SVP,Head-Res&Drug | 0 | $0 | 2 | $176,659 | $-176,659 |
| John Minardo | Chief Legal Officer | 0 | $0 | 3 | $223,102 | $-223,102 |
| Moukheibir Catherine | director | 0 | $0 | 2 | $517,694 | $-517,694 |
| MCCOURT Thomas A | Chief Executive Officer | 0 | $0 | 2 | $680,889 | $-680,889 |
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain …
Insider Activity of Ironwood Pharmaceuticals, Inc.
Over the last 12 months, insiders at Ironwood Pharmaceuticals, Inc. have bought $0 and sold $2.01M worth of Ironwood Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Ironwood Pharmaceuticals, Inc. have bought $11.71M and sold $4.33M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,920 shares for transaction amount of $60,204 was made by Duane Jon R (director) on 2024‑03‑06.
List of Insider Buy and Sell Transactions, Ironwood Pharmaceuticals, Inc.
| 2025-02-10 | Sale | MCCOURT Thomas A | Chief Executive Officer | 139,064 0.0889% | $1.76 | $244,753 | -8.76% | |
| 2025-02-10 | Sale | Shetzline Michael | SVP, CMO, Head-Res&Drug | 41,269 0.0264% | $1.76 | $72,633 | -8.76% | |
| 2025-02-10 | Sale | John Minardo | Chief Legal Officer | 38,938 0.0249% | $1.76 | $68,531 | -8.76% | |
| 2025-02-10 | Sale | Silver Ronald | Principal Accounting Officer | 12,048 0.0077% | $1.76 | $21,204 | -8.76% | |
| 2025-02-10 | Sale | Martini Gregory S. | Chief Financial Officer | 12,052 0.0077% | $1.76 | $21,212 | -8.76% | |
| 2024-11-18 | Sale | Emany Sravan Kumar | SVP, COO and CFO | 11,001 0.007% | $4.08 | $44,884 | -12.44% | |
| 2024-11-18 | Sale | Davis Andrew | SVP, Chief Business Officer | 5,360 0.0034% | $4.08 | $21,869 | -12.44% | |
| 2024-08-12 | Sale | John Minardo | Chief Legal Officer | 9,910 0.0063% | $4.27 | $42,316 | -5.31% | |
| 2024-08-12 | Sale | Silver Ronald | Principal Accounting Officer | 3,107 0.002% | $4.27 | $13,267 | -5.31% | |
| 2024-06-10 | Sale | McHugh Julie | director | 22,766 0.0138% | $6.29 | $143,198 | -35.17% | |
| 2024-06-07 | Sale | Moukheibir Catherine | director | 35,574 0.0233% | $6.61 | $235,144 | -33.23% | |
| 2024-06-06 | Sale | Moukheibir Catherine | director | 44,426 0.0276% | $6.36 | $282,549 | -34.26% | |
| 2024-05-20 | Sale | MCCOURT Thomas A | Chief Executive Officer | 67,618 0.0427% | $6.45 | $436,136 | -33.02% | |
| 2024-05-20 | Sale | Shetzline Michael | CMO,SVP,Head-Res&Drug | 16,128 0.0102% | $6.45 | $104,026 | -33.02% | |
| 2024-05-20 | Sale | John Minardo | Chief Legal Officer | 17,404 0.011% | $6.45 | $112,256 | -33.02% | |
| 2024-05-20 | Sale | Davis Andrew | SVP, Chief Business Officer | 22,725 0.0144% | $6.45 | $146,576 | -33.02% | |
| 2024-03-06 | Duane Jon R | director | 6,920 0.0045% | $8.70 | $60,204 | -46.75% | ||
| 2024-03-04 | Emany Sravan Kumar | SVP, Chief Financial Officer | 10,684 0.0069% | $9.38 | $100,216 | -50.32% | ||
| 2024-02-12 | Sale | MCCOURT Thomas A | Chief Executive Officer | 177,164 0.1118% | $15.24 | $2.7M | -67.21% | |
| 2024-02-12 | Sale | Shetzline Michael | CMO,SVP,Head-Res&Drug | 38,618 0.0244% | $15.24 | $588,538 | -67.21% |
Total: 360
*Gray background shows transactions not older than one year
Insider Historical Profitability
9.38%
| Emany Sravan Kumar | SVP, COO and CFO | 309572 0.1934% | $476,740.88 | 2 | 2 | <0.0001% |
| DENNER ALEXANDER J | 16390000 10.242% | $25.24M | 8 | 0 | +18.72% | |
| Ridgeback Capital Investments L.P. | 10 percent owner | 6842839 4.276% | $10.54M | 3 | 42 | <0.0001% |
| Hecht Peter M | Chief Executive Officer | 4696917 2.9351% | $7.23M | 1 | 16 | +9.03% |
| Owens Edward P | director | 218954 0.1368% | $337,189.16 | 4 | 0 | +34.25% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,051,022 | 1591 | -12.84% | $72.22M | |
$22,899,264 | 81 | 34.90% | $24.86M | |
$218,350,131 | 64 | 16.68% | $304.69M | |
$129,489,279 | 57 | 26.09% | $630.34M | |
$125,860,243 | 57 | -4.48% | $57.2M |
IRWD Institutional Investors: Active Positions
| Increased Positions | 118 | +44.36% | 15M | +8.73% |
| Decreased Positions | 119 | -44.74% | 21M | -12.12% |
| New Positions | 40 | New | 4M | New |
| Sold Out Positions | 39 | Sold Out | 3M | Sold Out |
| Total Postitions | 265 | -0.38% | 164M | -3.39% |
IRWD Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $34,326.00 | 14.4% | 23.04M | +117,478 | +0.51% | 2024-12-31 |
| Vanguard Group Inc | $29,112.00 | 12.21% | 19.54M | -2M | -11.34% | 2024-12-31 |
| Sarissa Capital Management Lp | $24,421.00 | 10.24% | 16.39M | 0 | 0% | 2024-12-31 |
| Pacer Advisors, Inc. | $17,479.00 | 7.33% | 11.73M | +450,949 | +4% | 2024-12-31 |
| Armistice Capital, Llc | $14,107.00 | 5.92% | 9.47M | +1M | +15.46% | 2024-12-31 |
| Renaissance Technologies Llc | $13,509.00 | 5.67% | 9.07M | +469,043 | +5.46% | 2024-12-31 |
| State Street Corp | $12,410.00 | 5.21% | 8.33M | -2M | -16.04% | 2024-12-31 |
| Braidwell Lp | $8,106.00 | 3.4% | 5.44M | +1M | +22.58% | 2024-12-31 |
| Kynam Capital Management, Lp | $6,981.00 | 2.93% | 4.69M | +1M | +27.13% | 2024-12-31 |
| Lsv Asset Management | $6,081.00 | 2.55% | 4.08M | -970,100 | -19.2% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.